The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Evaluate the Safety, Tolerability, Efficacy, and PK of FHL-301 in Parkinson's Disease Patients.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05931484
Recruitment Status : Not yet recruiting
First Posted : July 5, 2023
Last Update Posted : February 26, 2024
Sponsor:
Information provided by (Responsible Party):
Forest Hills Lab

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This is a phase 2, double-blind, multi-center, placebo-controlled clinical study to evaluate the safety, tolerability, efficacy, and PK of FHL-301 in adult patients with early-stage PD. Following screening, qualifying patients who meet all inclusion and exclusion criteria will enter the study and be randomized 1:1 to receive FHL-301 or Placebo at a starting dose of 200 mg BID (30 minutes before the morning and evening meals) during the 3-week titration period. To determine the tolerance of each participant for FHL-301, titration will increase by 200 mg BID every week until the maximum dose of 600 mg BID or the highest tolerated dose of 1200 mg daily is reached and maintained for 1 week. Thereafter, patients who complete the dose Titration Phase of the study will enter the Maintenance Phase and remain on the final titrated dose for up to 48 weeks post titration. If at any stage during the titration phase the participant cannot tolerate the increased dose, the dose will be decreased by 100 mg BID weekly until the highest tolerated dose is reached.

Condition or disease Intervention/treatment Phase
Parkinson Disease Drug: Gemfibrozil Drug: Placebo Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 32 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: This is a phase 2, double-blind, multi-center, placebo-controlled clinical study to evaluate the safety, tolerability, efficacy, and PK of FHL-301 in adult patients with early-stage PD. Following screening, qualifying patients who meet all inclusion and exclusion criteria will be randomized 1:1 ratio to receive FHL-301 or Placebo. The study is comprised of two phases: the Dose Titration Phase (DTP) in which participants will be started with a dose of 200 mg BID (30 minutes before the morning and evening meals) and increased during a 3-week treatment period. Patients who complete the DTP of the study will enter the Maintenance Phase and remain on the final titrated dose for up to 48 weeks post titration. If at any stage during the titration phase the participant cannot tolerate the increased dose, the dose will be decreased by 100 mg BID weekly until the highest tolerated dose is reached.
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2, Double-Blind, Multi-Center, Placebo-Controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of FHL-301 in Adult Patients With Parkinson's Disease
Estimated Study Start Date : November 1, 2024
Estimated Primary Completion Date : December 1, 2024
Estimated Study Completion Date : December 30, 2024

Resource links provided by the National Library of Medicine

Drug Information available for: Gemfibrozil

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: Active
Active
 Drug: Gemfibrozil
Oral Solution
Placebo Comparator: Placebo
Placebo
 Drug: Placebo
Daily dose of Placebo
Other Name: Placebo to match Gemfibrozil solution


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. The Unified Parkinson's Disease Rating Scale [ Time Frame: 52 weeks ]

    Change from Baseline in the Unified Parkinson's Disease Rating Scale Part III (motor examination) at maintenance Week 48 in the modified Full Analysis Set (mFAS) population.

    • Motor : range 0-132
    • 32 and below is mild and 59 and above is severe.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Eligible patients must fulfill the following inclusion criteria:

    • A diagnosis of clinically established PD in accordance with the Movement Disorder Society (MDS) ClinicalDiagnostic Criteria for PD (Confirmed by DaTscan).
    • Each patient must be able and willing to provide signed and dated informed consent prior to the study.
    • Female and male patients 40 to 75 years of age inclusive.
    • Female patients of childbearing potential must not be pregnant or lactating with a negative serum human chorionic gonadotropin (HCG) pregnancy test result at Screening.
    • Female patients of childbearing potential and male patients must use an adequate method of contraception from Screening until completion of the study. Acceptable methods of contraception are barrier methods (male condom, female condom, diaphragm, cervical cap, spermicide, or intrauterine device [IUD]), surgical sterility (documented doctor's report of vasectomy, hysterectomy, and/or bilateral oophorectomy), and/or postmenopausal status (defined as at least 1 year without menses as demonstrated by medical history or patient report).
    • Treatment naïve patients for PD
    • Hoehn and Yahr Stage of 1.0 to 2.0 at Screening

Exclusion Criteria:

  • Diagnosis is unclear, or a suspicion of other Parkinsonian syndrome exists, such as secondary Parkinsonism (caused by drugs, toxins, infectious agents, vascular disease, trauma, brain neoplasm), Parkinson-plus syndromes, or Huntington's disease.
  • The presence of a clear diagnosis of neurodegenerative diseases other than PD
  • Have undergone surgery for the treatment of PD (e.g., pallidotomy, deep brain stimulation, fetal tissue transplantation) or have undergone any other brain surgery at any time, even for non-PD conditions.
  • Current/history of psychiatric diagnosis of acute psychotic disorder or other primary psychiatric diagnoses, i.e., bipolar disorder or MDD, or other psychiatric, neurological or behavioral disorders/symptoms that may interfere with conduct of study.
  • Montreal Cognitive Assessment (MoCA) score < 23
  • Clinical chemistry assessments that indicate clinically significant major or unstable disease such as: abnormal white or red blood cell count; aspartate aminotransferase (AST), alanine aminotransferase (ALT), or alkaline phosphatase (ALP) above 3x the upper limit of normal; or estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73m2
  • Pre-existing diagnosis of gastrointestinal diseases which may hamper absorption of study medication, such as liver and gallbladder diseases (e.g., cholangitis and cholestasis), Crohn's disease or ulcerative colitis.
  • Female participants that are pregnant or planning to become pregnant.
  • Significant neurologic disease such as AD, stroke, brain tumor, multiple sclerosis or seizure disorder.
  • Major depression in past 12 months (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition [DSM-5] criteria), major mental illness such as schizophrenia, or recent (in past 12 months) alcohol or substance abuse.
  • Use of any investigational agents within 30 days prior to screening.
  • Sensitivity, intolerance, or allergies to FHL-301.
  • Patient with any history or current evidence of suicidal ideation in the last year.
  • Unwilling to complete any planned study assessments.
  • Any contraindication for undergoing a Magnetic resonance imaging (MRI) scan of the head.
  • Abnormal MRI findings in the mega cisterna, septum pellucidum, signs of severe cortical or subcortical atrophy, brain tumors, vascular diseases, trauma or arteriovenous malformations
  • Patient has any additional illnesses that in the Investigator's opinion would cause them to be at risk with treatment with FHL-301.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05931484


Contacts
Layout table for location contacts
Contact: Luis Rojas, PhD 305-510-4020 luisrojas@foresthillslab.com

Sponsors and Collaborators
Forest Hills Lab
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Forest Hills Lab
ClinicalTrials.gov Identifier: NCT05931484    
Other Study ID Numbers: FHL-301-001
First Posted: July 5, 2023    Key Record Dates
Last Update Posted: February 26, 2024
Last Verified: June 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Synucleinopathies
Neurodegenerative Diseases
 Gemfibrozil
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Cytochrome P-450 CYP2C8 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors